Sperm cryopreservation for men with nonmalignant, systemic diseases: a descriptive study

Pavithra Ranganathan1, Ayman M Mahran, Jorge Hallak

  • 1Center for Advanced Research in Human Reproduction and Infertility, Urological Institute, The Cleveland Clinic Foundation, Ohio 44195, USA.

Journal of Andrology
|January 10, 2002
PubMed

Insights

Sperm cryopreservation is a viable option for men with systemic diseases undergoing cytotoxic or immunosuppressive therapy. Pretreatment semen quality is adequate for assisted reproductive techniques, preserving future fertility potential.

Area of Science:

  • Reproductive Medicine
  • Andrology
  • Oncology Supportive Care

Background:

  • Cytotoxic and immunosuppressive therapies for nonmalignant systemic diseases can cause permanent infertility by suppressing spermatogenesis.
  • Sperm cryopreservation before treatment offers a potential solution for future fertility.
  • The suitability of pretreatment sperm for assisted reproductive techniques in this population is uncertain.

Purpose of the Study:

  • To assess the pretreatment semen quality of patients undergoing therapies that may impair fertility.
  • To compare patient semen quality with healthy donors and World Health Organization (WHO) reference values.
  • To evaluate variations in semen parameters among different patient subgroups.

Main Methods:

  • Collected semen samples from 23 patients with systemic diseases and 25 healthy donors.
  • Analyzed semen parameters including sperm count, motility, and motion kinetics.
  • Compared patient data against WHO reference values and donor data before and after cryopreservation.

Main Results:

  • Patient pretreatment semen quality was lower than healthy donors but within WHO normal ranges.
  • No significant differences in sperm parameters were observed across patient groups, except for lower sperm counts in diabetic patients (n=3).
  • Pretreatment semen quality is deemed adequate for assisted reproductive techniques.

Conclusions:

  • Sperm cryopreservation should be offered to reproductive-aged men at risk of treatment-induced infertility.
  • Pretreatment semen analysis is crucial for assessing fertility preservation options.
  • Further research with larger sample sizes is needed to confirm findings in specific patient subgroups.